Huang YuKun, Zhou Bin, Hong ShaoXian, Cai YaLi
Pediatric Intensive Care Unit, Xiamen Children's Hospital, Children's Hospital of Fudan University (Xiamen Branch), Xiamen, China.
Front Pediatr. 2024 Apr 5;12:1351478. doi: 10.3389/fped.2024.1351478. eCollection 2024.
Acute Necrotizing Encephalopathy (ANE), is a kind of severe Central Nervous System Disease. The commonest pathogen is the influenza virus. The pathogenesis of ANE is bound up to genetic susceptibility and cytokine storm. Interleukin-6 (IL-6) is deemed as the core function in cytokine storm of ANE and that plays a significant role in evaluating the severity of Influenza-Related ANE. Tocilizumab, an IL-6 antagonist, is known to be safe and effective in the treatment of ANE when used early and has an essential role in improving prognosis and preventing disability.
This case reports a 2 year 10 month old boy who developed ANE after being infected with influenza A virus (H1N1-2019). After treatment with Tocilizumab, the child's consciousness was clear, no convulsions occurred, the movement of limbs was improved, and the lesions of encephalopathy were significantly reduced.
The early use of Tocilizumab is safe and effective for the treatment of ANE caused by influenza virus.
急性坏死性脑病（ANE）是一种严重的中枢神经系统疾病。最常见的病原体是流感病毒。ANE的发病机制与遗传易感性和细胞因子风暴密切相关。白细胞介素-6（IL-6）被认为是ANE细胞因子风暴的核心因子，在评估流感相关ANE的严重程度中起重要作用。托珠单抗是一种IL-6拮抗剂，已知在早期使用时对ANE的治疗安全有效，在改善预后和预防残疾方面具有重要作用。
本病例报告了一名2岁10个月大的男孩，感染甲型流感病毒（H1N1-2019）后患上ANE。经托珠单抗治疗后，患儿意识清醒，未发生惊厥，肢体活动改善，脑病病变明显减轻。
早期使用托珠单抗治疗流感病毒引起的ANE安全有效。
Zotero 插件